Hydroxychloroquine (z0188) (DrugBank: Hydroxychloroquine)
23 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
34 | Neurofibromatosis | 0 |
41 | Giant cell arteritis | 0 |
43 | Microscopic polyangiitis | 0 |
44 | Wegener granulomatosis | 0 |
45 | Eosinophilic granulomatosis with Polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
48 | Primary antiphospholipid syndrome | 0 |
49 | Systemic lupus erythematosus | 1 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
66 | IgA nephropathy | 0 |
84 | Sarcoidosis | 0 |
89 | Lymphangioleiomyomatosis | 0 |
90 | Retinitis pigmentosa | 0 |
96 | Crohn disease | 0 |
218 | Alport syndrome | 0 |
222 | Primary nephrotic syndrome | 0 |
234 | Peroxisomal disease (except Adrenoleukodystrophy) | 0 |
254 | Porphyria | 0 |
271 | Ankylosing spondylitis | 0 |
298 | Hereditary pancreatitis | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01551069 (ClinicalTrials.gov) | March 2012 | 8/3/2012 | Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion | A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion | Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus | Drug: hydroxychloroquine (Z0188);Drug: Placebo | Sanofi | NULL | Completed | 18 Years | N/A | Both | 103 | Phase 3 | Japan |